Kiromic Biopharma Stock Profit Margin
KRBPDelisted Stock | USD 2.68 0.07 2.55% |
Kiromic Biopharma fundamentals help investors to digest information that contributes to Kiromic Biopharma's financial success or failures. It also enables traders to predict the movement of Kiromic Stock. The fundamental analysis module provides a way to measure Kiromic Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kiromic Biopharma stock.
Kiromic |
Kiromic Biopharma Company Profit Margin Analysis
Kiromic Biopharma's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
CompetitionBased on the latest financial disclosure, Kiromic Biopharma has a Profit Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The profit margin for all United States stocks is 100.0% lower than that of the firm.
Did you try this?
Run Cryptocurrency Center Now
Cryptocurrency CenterBuild and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
All Next | Launch Module |
Kiromic Fundamentals
Return On Equity | -11.3 | ||||
Return On Asset | -0.92 | ||||
Current Valuation | 9.55 M | ||||
Shares Outstanding | 1.18 M | ||||
Shares Owned By Insiders | 3.91 % | ||||
Shares Owned By Institutions | 68.00 % | ||||
Number Of Shares Shorted | 45.74 K | ||||
Price To Book | 15.11 X | ||||
EBITDA | (29.44 M) | ||||
Net Income | (34.73 M) | ||||
Cash And Equivalents | 6.51 M | ||||
Cash Per Share | 0.41 X | ||||
Total Debt | 9.41 M | ||||
Debt To Equity | 0.20 % | ||||
Current Ratio | 1.35 X | ||||
Book Value Per Share | (5.35) X | ||||
Cash Flow From Operations | (23.75 M) | ||||
Short Ratio | 0.93 X | ||||
Earnings Per Share | (39.68) X | ||||
Number Of Employees | 31 | ||||
Beta | 0.16 | ||||
Market Capitalization | 2.15 M | ||||
Total Asset | 11.97 M | ||||
Retained Earnings | (101.95 M) | ||||
Working Capital | (11.59 M) | ||||
Z Score | -21.07 | ||||
Net Asset | 11.97 M |
About Kiromic Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kiromic Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiromic Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiromic Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Kiromic Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kiromic Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kiromic Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Kiromic Stock
Moving against Kiromic Stock
0.67 | DRUG | Bright Minds Biosciences | PairCorr |
0.67 | SABSW | SAB Biotherapeutics | PairCorr |
0.63 | VCYT | Veracyte | PairCorr |
0.48 | VERA | Vera Therapeutics | PairCorr |
0.46 | DMAC | DiaMedica Therapeutics Upward Rally | PairCorr |
The ability to find closely correlated positions to Kiromic Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kiromic Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kiromic Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kiromic Biopharma to buy it.
The correlation of Kiromic Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kiromic Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kiromic Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kiromic Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Kiromic Stock
If you are still planning to invest in Kiromic Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kiromic Biopharma's history and understand the potential risks before investing.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |